Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

Krish Patel, MD, Radhakrishnan Ramchandren, MD, Michael Maris, MD, Alexander M. Lesokhin, MD, Gottfried R. von Keudell, MD PhD, Bruce D. Cheson, MD, Jeff Zonder, MD, Erlene K. Seymour, MD, Tina Catalano, MSc, Gloria H. Y. Lin, PhD, Bob Uger, PhD, Penka S. Petrova, PhD, Kathleen Roberge, ANP, MSc, Yaping Shou, MDPhD, Swami P. Iyer, MD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-136607

Published: 2020

Journal Articles

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Blood (2020) 136 (Supplement 1): 41–43.

https://doi.org/10.1182/blood-2020-136198

Published: 2020

Journal Articles

Intralesional Administration of the CD47 Antagonist TTI-621 (SIRPαFc) Induces Responses in Both Injected and Non-Injected Lesions in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Interim Results of a Multicenter Phase I Trial

Christiane Querfeld, MD PhD, John Thompson, MD, Matthew H. Taylor, MD, Raju Pillai, MD, Lisa DS Johnson, PhD, Tina Catalano, MSc, Penka S. Petrova, PhD, Theresa Thompson, Robert A. Uger, PhD, Yaping Shou, MD PhD, Oleg E. Akilov, MD

Blood (2018) 132 (Supplement 1): 1653.

https://doi.org/10.1182/blood-2018-99-116915

Published: 2018

Journal Articles

TTI-621 (SIRPαFc), an Immune Checkpoint Inhibitor Blocking the CD47 “Do Not Eat” Signal, Induces Objective Responses in Patients with Advanced, Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Stephen M Ansell, MD PhD, Ian W. Flinn, MD PhD, Michael B. Maris, MD, Owen A. O'Connor, MD, PhD, Alexander Lesokhin, MD, Anjali S. Advani, MD, Mark D. Minden, MD PhD, Mary Beth M. Percival, MD, Lisa DS Johnson, PhD, Tina Catalano, MSc, Meghan Irwin, BSc, EMBA, Penka S. Petrova, PhD, Robert A. Uger, PhD, Eric L Sievers, MD, Robert W. Chen, MD

Blood (2017) 130 (Supplement 1): 4116.

https://doi.org/10.1182/blood.V130.Suppl_1.4116.4116

Published: 2017

Journal Articles

A Single Direct Intratumoral Injection of TTI-621 (SIRPαFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Preliminary Findings Employing an Immune Checkpoint Inhibitor Blocking the CD47 "Do Not Eat" Signal

Christiane Querfeld, MD PhD, John Thompson, MD, Matthew Taylor, Raju Pillai, MD, Lisa DS Johnson, PhD, Tina Catalano, MSc, Penka S. Petrova, PhD, Robert A. Uger, PhD, Meghan Irwin, BSc, EMBA, Eric L Sievers, MD, Oleg E. Akilov, MD

Blood (2017) 130 (Supplement 1): 4076.

https://doi.org/10.1182/blood.V130.Suppl_1.4076.4076

Published: 2017

Journal Articles

Investigating the Efficacy of Anti-CD200 Immunotherapy in MRD Low and Risk B Cell Precursor ALL

Paraskevi Diamanti, PhD, Saifurrizal Saifurrizal, MD, Charlotte V. Cox, BSc, Penka S. Petrova, PhD, Robert A. Uger, PhD, Allison Blair, PhD

Blood (2017) 130 (Supplement 1): 3886.

https://doi.org/10.1182/blood.V130.Suppl_1.3886.3886

Published: 2017

Journal Articles

A Phase 1 Study of TTI-621, a Novel Immune Checkpoint Inhibitor Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Stephen Ansell, MD PhD, Robert W Chen, MD, Ian W. Flinn, MD PhD, Michael B. Maris, MD, Owen A. O'Connor, MD PhD, Lisa DS Johnson, PhD, Meghan Irwin, Penka S. Petrova, PhD, Robert A. Uger, PhD, Eric L Sievers, MD

Blood (2016) 128 (22): 1812.

https://doi.org/10.1182/blood.V128.22.1812.1812

Published: 2016

Journal Articles

Investigating the Effects of Anti-CD200 Therapy for Childhood ALL

Paraskevi Diamanti, BSc, PhD, Charlotte V. Cox, BSc, Benjamin C Ede, BSc, Penka S. Petrova, PhD, Robert A. Uger, PhD, Allison Blair, PhD BSc

Blood (2016) 128 (22): 4021.

https://doi.org/10.1182/blood.V128.22.4021.4021

Published: 2016

Journal Articles

Preclinical Characterization of TTI-281, a Novel, Orally Bioavailable BET Inhibitor: Predictive Biomarker Identification and Combination Treatment Analysis

Jaehyun Choi, PhD, Chunlei Wang, Zezhou Wang, PhD, Aaron D. Schimmer, MD PhD, Penka S. Petrova, PhD, Malik Slassi, PhD, Robert A. Uger, PhD

Blood (2016) 128 (22): 4719.

https://doi.org/10.1182/blood.V128.22.4719.4719

Published: 2016

Journal Articles

TTI-281, an Orally Bioavailable Bromodomain and Extraterminal Domain (BET) Inhibitor, Is a Promising Candidate for the Treatment of Multiple Myeloma

Zezhou Wang, PhD, Jaehyun Choi, PhD, Peter Dove, Chunlei Wang, Aaron D. Schimmer, MD PhD, Penka S. Petrova, PhD, Robert A. Uger, PhD, Malik Slassi, PhD

Blood (2016) 128 (22): 2095.

https://doi.org/10.1182/blood.V128.22.2095.2095

Published: 2016

Journal Articles

Blockade Of CD47 Using SIRPαFc: Role Of The Fc Region In Anti-Leukemic Activity and Tolerability

Robert A. Uger, PhD, Xinli Pang, MD, PhD, Mark Wong, PhD, Violetta House, Karen Dodge, Stephane Viau, Noel T. Vigo, Debbie Tam, Tran Truong, Liqing Jin, MD, Andrei V. Malko, Jenny Ho, MD, Tatiana K. Prasolava, PhD, Jayne S. Danska, PhD, Jean C.Y. Wang, MD PhD, Penka S. Petrova, PhD

Blood (2013) 122 (21): 3935.

https://doi.org/10.1182/blood.V122.21.3935.3935

Published: 2013

NARROW

Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Intralesional Administration of the CD47 Antagonist TTI-621 (SIRPαFc) Induces Responses in Both Injected and Non-Injected Lesions in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Interim Results of a Multicenter Phase I Trial

TTI-621 (SIRPαFc), an Immune Checkpoint Inhibitor Blocking the CD47 “Do Not Eat” Signal, Induces Objective Responses in Patients with Advanced, Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

A Single Direct Intratumoral Injection of TTI-621 (SIRPαFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Preliminary Findings Employing an Immune Checkpoint Inhibitor Blocking the CD47 "Do Not Eat" Signal

Investigating the Efficacy of Anti-CD200 Immunotherapy in MRD Low and Risk B Cell Precursor ALL

A Phase 1 Study of TTI-621, a Novel Immune Checkpoint Inhibitor Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Investigating the Effects of Anti-CD200 Therapy for Childhood ALL

Preclinical Characterization of TTI-281, a Novel, Orally Bioavailable BET Inhibitor: Predictive Biomarker Identification and Combination Treatment Analysis

TTI-281, an Orally Bioavailable Bromodomain and Extraterminal Domain (BET) Inhibitor, Is a Promising Candidate for the Treatment of Multiple Myeloma

Blockade Of CD47 Using SIRPαFc: Role Of The Fc Region In Anti-Leukemic Activity and Tolerability

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only